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Background. Management of severe malaria with limited resources requires comprehensive planning. Expected length of stay 
(LOS) and the factors influencing it are useful in the planning and optimisation of service delivery.
Methods. A secondary, competing-risk approach to survival analysis was performed for 1217 adult severe malaria patients from 
the South-East Asia Quinine Artesunate Malaria Trial.
Results. Twenty percent of patients died; 95.4% within 7 days compared to 70.3% of those who were discharged. Median time 
to discharge was 6 days. Compared to quinine, artesunate increased discharge incidence (subdistribution-Hazard ratio, 1.24; [95% 
confidence interval 1.09–1.40]; P = .001) and decreased incidence of death (0.60; [0.46–0.80]; P < .001). Low Glasgow coma scale 
(discharge, 1.08 [1.06–1.11], P < .001; death, 0.85 [0.82–0.89], P < .001), high blood urea-nitrogen (discharge, 0.99 [0.99–0.995], 
P <  .001; death, 1.00 [1.00–1.01], P =  .012), acidotic base-excess   (discharge, 1.05 [1.03–1.06], P <  .001; death, 0.90 [0.88–0.93], 
P < .001), and development of shock (discharge, 0.25 [0.13–0.47], P < .001; death, 2.14 [1.46–3.12], P < .001), or coma (discharge, 
0.46 [0.32–0.65], P < .001; death, 2.30 [1.58–3.36], P < .001) decreased cumulative incidence of discharge and increased incidence of 
death. Conventional Kaplan-Meier survival analysis overestimated cumulative incidence compared to competing-risk model.
Conclusions. Clinical factors on admission and during hospitalisation influence LOS in severe malaria, presenting targets to 
improve health and service efficiency. Artesunate has the potential to increase LOS, which should be accounted for when planning 
services. In-hospital death is a competing risk for discharge; an important consideration in LOS models to reduce overestimation of 
risk and misrepresentation of associations.
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Malaria remains a prominent global health issue, with 3.2 billion 
people at risk of death and disability worldwide [1, 2], mostly 
in areas with fewer resources to manage it [3]. It is responsible 
for up to 50% of all hospital admissions in endemic areas [4], 
encumbering healthcare systems with an estimated global 
case-management cost of $300 million per year [5].
With finite resources available, planning efficient service deliv-
ery requires careful resource allocation, informed by anticipated 
hospital bed requirements and expected resource use [6, 7]. This 
is predicted using estimated length of stay (LOS) [8, 9], a metric 
widely used in hospital capacity planning [10] and recommended 
by the World Health Organization (WHO) to indicate health ser-
vice quality and efficiency [11].
Longer LOS increases resource consumption [12], so target-
ing modifiable factors that influence LOS can improve health 
system efficiency and reduce expenditure [13]. However, there 
is little information on factors that affect LOS in severe malaria, 
the pathway to death in malaria patients [14]. Unsurprisingly, 
severe malaria is more expensive to treat than uncomplicated 
malaria, primarily driven by differences in LOS [15]. Yet, most 
studies focus on predictors of mortality [16], resulting in insuf-
ficient evidence on LOS in severe malaria to make informed 
decisions.
Treatment consumes more than a third of the global malaria 
budget [17], making it an important policy consideration. 
Intravenous artesunate is superior to quinine; it reduced mor-
tality by 34.7% in Asia [18] and 22.5% in African children [19], 
clears parasites faster, causes fewer adverse effects, and is easier 
to administer [18]. WHO has since endorsed artesunate as first-
line treatment for severe malaria [20], but by 2016, less than 
65% of countries had adopted this recommendation into policy 
[3]. Understanding artesunate’s impact on LOS could contrib-
ute to these policy decisions and aid service-delivery planning.
Methods for estimating LOS conventionally analyze time 
to discharge; time to death in-hospital does not contribute 
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to LOS estimates. Instead, deaths are censored in a standard 
survival analysis approach [21], ignoring the influence that 
time to death has on resource use and the impact deaths have 
on the cumulative incidence of discharge. The complement 
of the Kaplan-Meier survival curve is often used to estimate 
cumulative incidence, assuming that the probability of the 
primary event is the same in the censored individuals as in 
those still under observation (ie, censoring events are ran-
dom) [22]. When a patient dies in-hospital, discharge is no 
longer possible, so censoring the competing event of death 
violates this assumption and leads to overestimation of dis-
charge incidence in a Kaplan-Meier model [23]. Death and 
discharge “compete” with each other, necessitating the use of 
a competing-risk approach that generates results that reflect 
real-world situations where competing events are pres-
ent [24]. Because more accurate information means better 
informed decisions on resource allocation [25], we modeled 
LOS in severe malaria accounting for the competing event 
of death.
METHODS
This was a retrospective, secondary analysis of the South-East 
Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) data-
set, modeling LOS as time to discharge or death in-hospital, 
with competing-risk methodology.
Data
SEAQUAMAT was a randomized, controlled trial that found 
that artesunate decreased death by 34.7% compared to quinine 
[18]. Patients from Myanmar, Bangladesh, India, and Indonesia 
(where 97% of the confirmed malaria cases in the Asia-Pacific 
region occur [26]) with severe falciparum malaria (diagnosed 
by clinical criteria and a positive rapid test) were enrolled 
between June 2003 and May 2005 [18]. In this analysis, 234 
children aged <16 years were excluded to prevent confounding 
of associations with variables that have age-dependent normal 
ranges. Seven patients refused treatment and died at home; 
they did not experience either event of interest (discharge or 
death in-hospital) and were excluded from this analysis in add-
ition to patients who had incomplete data on time to outcome. 
Ultimately, we analyzed 1217 patients (Figure 1).
Statistical Methods
A literature search using the Cochrane Library, PubMed, and 
Google Scholar databases up to 1 August 2017 determined fac-
tors associated with malaria LOS (Supplementary Tables 1 and 2). 
Objective measures were chosen to represent clinical factors 
where available (eg, blood urea nitrogen [BUN] representing 
renal function); base-excess was chosen over pH as a better meas-
ure of metabolic acidosis [27]. Complications that develop dur-
ing hospitalization, not reported in the literature but available in 
the dataset, were explored for their potential influence on LOS.
1461 paents aged >2 years with severe falciparum malaria,
enrolled and randomized to receive quinine or artesunate in the SEAQUAMAT 
randomized controlled trial.
Exclusion for secondary analysis:
Paents aged <16 years n = 234
Incomplete data on the me to
outcome: n = 3
Did not experience discharge or 
death in hospital: n = 7
976 paents with the outcome of 
discharge
241 paents with the outcome
of death
1217 paents analyzed (607 in the quinine arm and 610 in the artesunate arm)
Figure 1. Eligibility flow chart for the secondary analysis of the South-East Asian Quinine Artesunate Malaria Trial dataset. Abbreviation: SEAQUAMAT, South-East Asian 
Quinine Artesunate Malaria Trial.
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After discussion with clinicians, 19 variables were cho-
sen for investigation: demographic factors (country, age, 
and gender), clinical factors on admission (systolic blood 
pressure, respiratory rate, temperature, Glasgow coma scale 
[GCS], and seizures), admission laboratory results (BUN, 
base-excess, parasite count, and hemoglobin), clinical con-
ditions that developed during hospitalization (shock, coma, 
seizures, sepsis, and anemia), and treatment (previous 
Table 1. Baseline Characteristics of the Adult Population of the South-East Asian Quinine Artesunate Malaria Trial Dataset
Variable Whole Sample Discharged Died P Value
Demographics
 Country (total n) 1217 976 241 <.001
 Myanmar n (%) 466 (38.3) 395 (40.5) 71 (29.5)
 Bangladesh n (%) 418 (34.4) 302 (30.9) 116 (48.1)
 India n (%) 137 (11.3) 105 (10.8) 32 (13.3)
 Indonesia n (%) 196 (16.1) 174 (17.8) 22 (9.1)
Age in years (total n) 1217 976 241 <.001
 Median and IQR 28 (21;40) 27 (21;38) 30 (23;45)
Gender (total n) 1217 976 241 .835
 Females (reference) n (%) 292 (24.0) 234 (24.0) 58 (24.1)
 Males n (%) 925 (76.0) 742 (76.0) 183 (75.9)
Clinical factors on admission
 Systolic blood pressure in mmHg (total n) 1207 971 236 .224
 Median and IQR 100 (90;120) 100 (90;120) 110 (92;120)
 Respiratory rate in breaths/minute (total n) 1215 975 240 <.001
 Median and IQR 24 (20;32) 24 (20;32) 28 (22;36)
 Temperature in C (total n) 1215 975 240 .023
 Mean and SD 38.05 (1.18) 38.09 (1.19) 37.90 (1.12)
 Glasgow Coma Scale score (total n) 1217 976 241 <.001
 Median and IQR 12 (9;15) 13 (9.5;15) 8 (6;11)
 Seizures (total n) 1217 976 241 .258
 Seizures present n (%) 114 (9.4) 85 (8.7) 29 (12.0)
Laboratory results on admission
 Blood urea nitrogen mg/dL (total n) 1157 933 224 <.001
 Median and IQR 30 (17;60) 35 (15;45) 71 (37.5;107.5)
 Base-excess mmol/L (total n) 1103 890 213 <.001
 Mean and SD -4.49 (6.95) -2.83 (5.53) -11.42 (7.93)
 Log parasite count (total n) 1153 921 232 <.001
 Mean and SD 10.56 (2.41) 10.37 (2.38) 11.31 (2.38)
Haemoglobin mg/dL(total n) 1142 920 222 .631
 Mean and SD 10.19 (3.31) 10.21 (3.33) 10.09 (3.24)
Clinical conditions developed during admission
 Shock noted (total n) 1217 976 241 <.001
 Shock developed n (%) 54 (4.4) 11 (1.1) 43 (17.8)
 Coma noted (total n) 1217 976 241 <.001
 Coma developed n (%) 103 (8.5) 43 (4.4) 60 (24.9)
 Seizures noted (total n) 1217 976 241 <.001
 Seizures developed n (%) 58 (4.7) 23 (2.4) 35 (14.5)
 Sepsis noted (total n) 1217 976 241 <.001
 Sepsis developed n (%) 85 (7.0) 49 (5.0) 36 (14.9)
Anaemia noted (total n) 1217 976 241 .911
 Anaemia developed n (%) 29 (2.4) 23 (2.4) 6 (2.5)
Treatment
 Previous effective antimalarials (total n) 1217 976 241 .675
 Previous treatment given n (%) 216 (17.8) 171 (17.5) 45 (18.7)
 Study treatment (total n) 1217 976 241 .001
 Quinine (reference) n (%) 607 (49.9) 460 (47.1) 147 (61.0)
 Artesunate n (%) 610 (50.1) 516 (52.9) 94 (39.0)
The bold values are those that are significant results (ie, P < .05).
Abbreviations: IQR, inter-quartile range; SD, standard deviation.
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antimalarial treatment and treatment with artesunate or the 
control, quinine).
Normally distributed variables were summarized with means 
and standard deviations. Non-normally distributed variables 
were summarized with medians and interquartile ranges (IQRs) 
or log-transformed to ensure a normal distribution (eg, parasite 
count). χ2 tests were used to examine categorical variable asso-
ciations. Half a day was added to the LOS of patients discharged 
on the same day as admission rather than excluding them from 
analysis, as it was assumed that time must pass before an event 
could be observed.
Cumulative incidence illustrates the pattern of events over 
time and has been suggested as more relevant for planning 
purposes than the event rate alone [28]. Cumulative incidence 
is traditionally represented by the complement of the Kaplan-
Meier curve, and this was calculated and compared to a com-
peting-risk model of cumulative incidence.
Associations were examined with cause-specific hazard (CSH) 
analysis using Cox proportional hazards regression [22, 24], 
describing the hypothetical probability of an event in a world 
where other events do not exist and quantifying a variable’s 
effect on the hazard (rate) of an outcome (cause of failure) [28]. 
Subdistribution-Hazard (SDH) ratios, estimated with a Fine 
and Gray model, demonstrate associations with cumulative 
incidence accounting for competing risks [29], where a ratio 
greater than 1 indicates a positive effect.
Univariable CSH and SDH analyses were performed for each 
outcome (Supplementary Tables 3 and 4). Factors with a significant 
effect (P < .05) were assessed in a multivariable model for discharge 
and death separately. Treatment (the randomized variable) and 
country were adjusted for as fixed effects throughout all models.
Analysis was performed using Stata, version 12, statistical 
software package. Confidence intervals (CIs) were reported as 
95%, and the threshold for significance was P <  .05. Findings 
were reported according to the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) Statement 
Cohort Studies checklist [30].
Local ethics committees and the Oxford Tropical Research 
Ethics Committee approved the original study. Written, 
informed consent was provided by patients, or their attendant 
relative, on enrollment into the original study [18], and there 
was no further recruitment of participants for this analysis. 
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Figure 2. Cumulative incidence of any event (discharge or death in-hospital), discharge (accounting for death), and death (accounting for discharge), estimated using 
Kaplan-Meier and competing-risks methods.
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Permission to use the data was obtained from the Mahidol-
Oxford Research Unit.
RESULTS
Of the 1217 patients analyzed, 976 (80.2%) were discharged and 
241 (19.8%) died in-hospital. Most patients were male (76.0%) 
and recruited from Myanmar (38.3%); the median age was 
28 years (range, 16–87 years). A  total of 235 patients (19.3%) 
developed 1 or more complications while admitted in hospi-
tal (Table 1). The median LOS (death or discharge) was 5 days 
(IQR 3–7, range 0.4–54 days).
Those who died were older than those who survived (median 
age 30 vs 27 years), with a lower GCS (median score 8 vs 13), worse 
renal function (median BUN 71 mg/dL vs 35 mg/dL), more severe 
acidosis (mean base-excess −11.42 vs −2.83), a higher parasite 
count (geometric mean 81737 vs 31983 parasites/µL), developed 
more clinical complications during  admission (49.8% vs 11.8%), 
and were more likely to receive quinine (61.0% vs 39.0% receiving 
artesunate; Table 1).
Time to Discharge
The median time to discharge was 6  days (IQR 4–9, range 
0.5–54 days), with 80% of the patients cumulatively discharged 
(Figure  2). The Kaplan-Meier model alternatively estimated 
cumulative discharge incidence as 100%. Time to discharge had 
a right skewed distribution, with most patients discharged on 
day 3 (16.1%) and most discharged in the first week (70.2%), 
with a secondary peak at 14 days (8.8%; Figure 3).
The adjusted rate of discharge was increased 5% for every unit 
increase in the GCS score (cause-specific hazard ratio [CSHR] 
1.05; [1.02–1.07]; P < .001). It was decreased 1% for every unit 
increase in BUN (CSHR: 0.99; [0.99–0.996]; P < .001), 31% by 
development of coma (CSHR: 0.69; [0.49–0.97]; P = .034), 40% 
by development of seizures (CSHR: 0.60; [0.38–0.93]; P = .024), 
and 55% with development of sepsis (CSHR: 0.45; [0.33–0.63]; 
P =< 0.001; Table 2).
Cumulative incidence of discharge was increased 8% for 
every unit increase in GCS score (subdistribution-Hazard ratio 
[SDHR], 1.08; [1.06–1.11]; P  <  .001) and 5% for every unit 
increase in base-excess (SDHR: 1.05; [1.03–1.06]; P < .001). It 
was decreased 1% per unit increase in BUN (SDHR: 0.99; [0.99–
0.995]; P < .001), 75% with development of shock (SDHR: 0.25; 
[0.13–0.47]; P  <  .001), 54% by development of coma (SDHR: 
0.46; [0.32–0.65]; P  <  .001), 45% by development of seizures 
(SDHR: 0.55; [0.38–0.81]; P = .002), and 54% by development 
of sepsis (SDHR: 0.46; [0.32–0.65]; P < .001; Table 2).
Median time to discharge was 5  days for patients with a 
normal GCS (score of 15), 6 days for those with a low score 
(GCS 8–14), and 7 days in those with coma on presentation 
(GCS <8). Those who developed shock or seizures each had 
a median time to discharge of 14 days, those who developed 
sepsis had 11 days and those who developed a coma during 
hospitalisation had a median time to discharge of 10 days. 
Most who developed complications (81.8% for shock, 67.4% 
for coma, 78.3% for seizures, and 59.2% for sepsis) were dis-
charged after 7 days.
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Figure 3. Distribution of time to discharge and time to death, in days.
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The median time to discharge was 6  days for both treat-
ments, ranging from 0.5 to 54  days for artesunate and 1 to 
45 days for quinine. There was no difference in proportions of 
patients discharged after 7 days in the artesunate (30.8%) and 
quinine (28.7%) arms (P = .470). Treatment was not associated 
with the rate of discharge (CSHR: 1.08; [0.94–1.25]; P = .253), 
but artesunate did increase cumulative incidence of discharge 
(SDHR: 1.24; [1.09–1.40]; P = .001; Table 2), resulting in 85.0% 
of artesunate recipients ultimately discharged compared to 
76.0% for quinine recipients (Figure 4).
Time to Death
The cumulative incidence of death was 20%; alternatively esti-
mated as 40% using the Kaplan-Meier approach (Figure 2). The 
mean time to death was 2.5 days (standard deviation, 3.4 days), 
ranging from 0.5 to 30 days. Time to death was right skewed, 
with most patients dying on the first day after admission 
(31.1%) and 95.4% dying in the first week (Figure 3).
The adjusted rate of death at any point was decreased 14% 
for every unit increase in GCS score (CSHR: 0.86; [0.82–0.90]; 
P  <  .001) and 10% per unit increase in base-excess (CSHR: 
0.90; [0.88–0.92]; P  <  .001). Development of shock increased 
the adjusted rate of death 2.11 times ([1.38–3.21]; P = .001) and 
development of coma 2.28 times ([1.53–3.40]; P < .001; Table 3).
The cumulative incidence of death was decreased 15% for every 
unit increase in GCS score (SDHR: 0.85; [0.82–0.89]; P < .001) and 
10% per unit increase in base-excess (SDHR: 0.90; [0.88–0.93]; 
P  <  .001). Development of shock increased the cumulative inci-
dence of death 2.14 times ([1.46–3.12]; P < .001) and development 
of coma 2.30 times ([1.58–3.36]; P < .001; Table 3). Significant vari-
ables predictive of each outcome are summarized in Table 4.
Artesunate had a wider range of time to death (0.5–30 days) 
than quinine (0.5–17 days), and significantly more patients in 
the artesunate arm died after 7 days (8.5%) than in the quinine 
arm (2.0%; P = .019). Artesunate significantly decreased the rate 
and cumulative incidence of death (Figure  4), with adjusted 
CSH and SDH ratios both 0.60 (Table 3).
DISCUSSION
LOS is important in planning healthcare delivery [7], with strat-
egies to reduce LOS proving effective in alleviating pressure on 
Table 2. Multivariable Analysis for Time to Discharge, Using a Conventional Cox Regression Model to Obtain a Cause-specific Hazard Ratio, and a Fine 
and Gray Competing-risks Method to Obtain a Subdistribution-Hazard Ratio
Covariate
Cause-specific Hazard (Rate of Discharge)
Subdistribution-Hazard (Association With 
 Cumulative Incidence of Discharge)
CSH Ratio P Value SDH Ratio P Value
Demographics
Country
 Myanmar (reference)
 Bangladesh 1.95 (1.61–2.34) <.001 1.58 (1.33–1.88) <.001
 India 2.17 (1.69–2.79) <.001 2.35 (1.92–2.86) <.001
 Indonesia 3.29 (2.64–4.10) <.001 2.80 (2.27–3.45) <.001
Age NS 1.00 (0.99–1.00) .270
Clinical factors on admission
Systolic blood pressure NS 0.99 (0.99–0.997) <.001
Respiratory rate NS 1.01 (1.00–1.02) .034
Temperature 1.07 (1.01–1.14) .022 1.12 (1.05–1.17) <.001
Glasgow coma scale 1.05 (1.02–1.07) <.001 1.08 (1.06–1.11) <.001
Seizures NS 0.98 (0.77–1.24) .876
Laboratory results on admission
Blood urea nitrogen 0.99 (0.99–0.996) <.001 0.99 (0.99–0.995) <.001
Base-excess 1.01 (1.00–1.03) .077 1.05 (1.03–1.06) <.001
Log parasite count 0.98 (0.95–1.01) .147 0.98 (0.95–1.01) .183
Haemoglobin 1.02 (1.00–1.04) .123 NS
Clinical conditions developed during admission
Shock developed 0.59 (0.30–1.14) .116 0.25 (0.13–0.47) <.001
Coma developed 0.69 (0.49–0.97) .034 0.46 (0.32–0.65) <.001
Seizures developed 0.60 (0.38–0.93) .024 0.55 (0.38–0.81) .002
Sepsis developed 0.45 (0.33–0.63) <.001 0.46 (0.32–0.65) <.001
Treatment
Quinine (reference) NS but adjusted for in the  
multivariable modelArtesunate 1.24 (1.09–1.40) .001
The bold values are those that are significant results (ie, P < .05).
Abbreviations: CSH, cause-specific hazard; NS, non-significant on univariable analysis and thus not included in the multivariable model; SDH, subdistribution hazard.
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bed capacity [13]. Patients who die or who are discharged both 
contribute to bed occupancy and resource use. Thus, both met-
rics are important for planning, and a competing-risk approach, 
accounting for both, produces estimates relevant to real-world 
service planning [7].
In contexts similar to this study, a median LOS (time to dis-
charge or death in-hospital) of 5 days, a median time to dis-
charge of 6 days, and a mean time to death of 2.5 days (the 
proportion of deaths was too low to calculate a median) can 
be expected. Planners can also expect most severe malaria 
patients to be discharged and most deaths to occur within 
the first week, demonstrated by the cumulative incidence 
pattern (Figure 2), which provides data along with expected 
LOS to anticipate bed availability, the timing and quantity of 
resources required, and to project the budget needed to man-
age expected cases [9].
These predictions need to account for factors that influence 
LOS [9]. As expected, a lower cumulative incidence of discharge 
and higher incidence of death were found in sicker patients; 
individuals with lower GCS, renal dysfunction (BUN >21 mg/
dL), and acidosis (base-excess <−3). In addition to the develop-
ment of anemia, patients who developed clinical complications 
also had longer LOS and reduced incidence of discharge, and, 
in contrast with the overall sample, most were discharged after 
7 days. These insights offer targets for screening and manage-
ment of conditions to reduce LOS and relieve pressure on the 
need for hospital beds [13].
Artesunate decreases mortality compared to quinine [18], 
and a greater proportion of patients in the artesunate arm died 
after 7  days, with a wider range of outliers. It could be rea-
soned that artesunate prolonged time to death of patients who 
would otherwise have died earlier. It could also be inferred 
that patients who might have died had they received quinine 
but survived because of artesunate’s mortality benefits may be 
sicker than other patients who survived to discharge, taking 
longer to recuperate.
The median time to discharge was 6 days for both treatment 
arms. However, median times on their own can be misleading, 
only describing 1 time point and offering no information about 
event distribution [31]. Cumulative incidence illustrates the pat-
tern of events, and exploration using a competing-risk approach 
revealed that artesunate increased the cumulative incidence of 
discharge compared to quinine by 8.8% (Table 3 and Figure 4).
This is an important consideration; changing to artesunate 
as first-line treatment should reduce mortality incidence, in 
turn, increasing the number of patients discharged. As severe 
malaria patients stay longer if they survive to discharge than if 
they die (Figure 3), this would lengthen overall LOS. Combined 
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with the prolonged range of time to discharge in the artesunate 
arm, artesunate has the potential to significantly lengthen LOS 
in severe malaria patients.
Choice of first-line treatment is based on multiple factors, 
including impact on health outcomes, availability, ease of use, 
cost [32], and resource consumption, such as LOS [9]. While 
artesunate is justified as first-line treatment by improvements in 
health (reduced mortality [18] and increased cumulative inci-
dence of discharge), the potential to increase overall LOS and 
subsequently the use of resources must be accounted for when 
planning services.
Only assessing time to discharge with conventional Cox 
regression means that the contribution of time to death on 
resource use would be overlooked and that systolic blood pres-
sure, respiratory rate, base-excess, development of shock, and 
choice of treatment would not have been considered in service 
planning, as they were nonsignificant in the CSH model for 
discharge (Table  4). A  less nuanced analysis results from not 
exploring time to death and the competing-risk model, leading 
to different conclusions on valuable predictors, such as artesu-
nate’s influence on LOS. This could potentially influence the 
planning of strategies to reduce LOS and maximize resource 
efficiency.
Another limitation of using conventional survival analysis in 
the presence of competing events is overestimation of cumu-
lative incidence. The Kaplan-Meier complement overestimated 
cumulative incidence of both discharge (100% compared to 
80% estimated by the competing risk approach) and death (40% 
compared to 20% estimated by the competing risk approach). 
Added together, the sum of death and discharge occurring (the 
only 2 possible outcomes) is an impossible 140%, illustrating 
the lack of precision when competing events are not accounted 
for (Figure 2).
Competing events are found in many studies published 
in high-impact journals [33] and are usually inappropriately 
treated as censored observations [21]. Despite misunderstand-
ings of the required Kaplan-Meier assumptions, a lack of aware-
ness of the competing-risk approach and the historically poor 
availability of competing-risk software packages [34], compet-
ing-risk methods have been increasingly used to analyze non-
communicable diseases [22, 23, 35, 36]. However, studies that 
apply it to communicable-disease analysis are still limited.
CSH analysis reveals insights into etiological associations 
between variables and discharge [24]; however, these are based 
on a hypothetical world where other events do not take place. 
A  proportion of malaria patients will die, influencing the 
Table 3. Multivariable Analysis for Time to Death, Using a Conventional Cox Regression Model to Obtain a Cause-specific Hazard Ratio, and a Fine and 
Gray Competing-risks Method to Obtain a Subdistribution-Hazard Ratio
Covariate
Cause-specific Hazard (Rate of Death)
Subdistribution-Hazard (Association With 
 Cumulative Incidence of Death)
CSH Ratio P Value SDH Ratio P Value
Demographics
Country
 Myanmar (reference)
 Bangladesh 1.72 (1.15–2.57) .008 1.68 (1.15–2.45) .007
 India 0.69 (0.41–1.17) .165 0.66 (0.41–1.05) .081
 Indonesia 0.98 (0.55–1.74) .941 0.91 (0.56–1.47) .7691
Age 1.01 (1.00–1.02) .044 1.01 (1.00–1.02) .044
Clinical factors on admission
Systolic blood pressure 1.01 (1.00–1.02) .004 1.01 (1.00–1.02) .001
Respiratory rate 1.01 (0.99–1.02) .404 1.01 (0.99–1.02) .318
Temperature 0.86 (0.74–1.00) .047 0.84 (0.73–0.97) .021
Glasgow coma scale 0.86 (0.82–0.90) <.001 0.85 (0.82–0.89) <.001
Laboratory results on admission
Blood urea nitrogen 1.00 (1.00–1.01) .038 1.00 (1.00–1.01) .012
Base-excess 0.90 (0.88–0.92) <.001 0.90 (0.88–0.93) <.001
Log parasite count 1.07 (1.00–1.15) .061 1.08 (1.00–1.17) .059
Clinical conditions developed during admission
Shock developed 2.11 (1.38–3.21) .001 2.14 (1.46–3.12) <.001
Coma developed 2.28 (1.53–3.40) <.001 2.30 (1.58–3.36) <.001
Seizures developed 1.40 (0.91–2.16) .121 1.45 (0.98–2.15) .065
Sepsis developed 0.99 (0.63–1.55) .964 1.06 (0.68–1.64) .802
Treatment
Quinine (reference)
Artesunate 0.60 (0.45–0.80) .001 0.60 (0.46–0.80) <.001
The bold values are those that are significant results (ie, P < .05).
Abbreviations: CSH, cause-specific hazard; SDH, subdistribution hazard.
Competing-Risk Analysis of Malaria LOS • CID 2018:67 (1 October) • 1061
cumulative incidence of discharge [33]. This makes SDH ana-
lysis, associated with cumulative incidence, particularly useful 
for planning in contexts where competing events exist [22]. It is 
imperative to explore both analyses to holistically understand 
the LOS in severe malaria.
There were limitations to our study. A  number of the fac-
tors that affect malaria LOS found in the literature search 
(Supplementary Table 2) were not available in this dataset and 
thus not analyzed. Furthermore, post-treatment bias could be 
introduced by the variables that developed during hospitaliza-
tion. To mitigate this, all analyses were adjusted for treatment 
as a fixed effect.
The sample was confined to the Asia-Pacific region, poten-
tially limiting generalizability to Africa where 90% of cases 
occur [1]. At the same time, patients came from multiple sites 
across South-East Asia, resulting in large intercountry differ-
ences that could confound findings. Variation could be due 
to differences in clinical factors on admission (Supplementary 
Table 5) or explained by intrinsic differences in country disease 
profiles and services offered [2]. This was addressed by adjust-
ing all analyses for the sample country as a fixed effect; how-
ever, the implication that LOS is affected by the setting should 
be considered when translating results to decision-making in a 
specific context.
CONCLUSIONS
LOS in severe malaria is influenced by demographic, clinical, 
and treatment factors that, along with cumulative incidence and 
expected time to both discharge and death, should be incorpo-
rated into planning to improve service efficiency. These met-
rics are also useful in decisions on treatment choice; artesunate 
increases cumulative incidence of discharge and decreases the 
cumulative incidence of death, reinforcing its recommendation 
as first-line treatment. However, its potential to increase overall 
LOS and the use of resources should be accounted for when 
planning malaria services.
Exploration of both CSH and SDH analyses can aid 
holistic understanding of variable relationships with LOS. 
Competing risks should be considered when designing and 
interpreting communicable-disease studies, as ignoring them 
leads to overestimation of cumulative incidence and misrep-
resentation of variable associations, LOS, and the pattern of 
discharge and death over time. This, in turn, can lead to dis-
parate conclusions, which have important implications for 
the policy decisions that impact the planning of malaria ser-
vice delivery.
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